Dopaminergic mechanism of reward-related incentive learning: Focus on the dopamine d3 receptor

被引:0
|
作者
Richard J. Beninger
Tomek J. Banasikowski
机构
[1] Queen’s University,Departments of Psychology
[2] Queen’s University,Psychiatry
[3] Queen’s University,Centre for Neuroscience Studies
来源
Neurotoxicity Research | 2008年 / 14卷
关键词
ABT-127; BP 897; CJB 090; NGB 2904; PNU 99194-A; RGH-237; SB-277011-A; ST 198;
D O I
暂无
中图分类号
学科分类号
摘要
Dopamine D3 receptors (Drd3) have been implicated in the control of responding by drug-related conditioned incentive stimuli. We review recent studies of the effects of Drd3 antagonists or partial agonists on the control of self-administration of intravenous (IV) cocaine, IV morphine and oral ethanol on reward-rich and lean schedules, in reinstatement tests, on second-order schedules and on the acquisition and expression of conditioned place preference (CPP) and conditioned motor activity. For comparison, related studies where conditioned stimuli are based on nutritional reward also are considered. When self-administration depends more heavily on conditioned cues for its maintenance, for example on second-order schedules or lean ratio schedules, Drd3 antagonists or partial agonists reduce responding. Although data are limited, similar effects may be seen for responding for cues based on drugs or nutritional rewards. Drd3 agents also block the ability of conditioned cues to reinstate responding for cocaine or food. Published results suggest that Drd3 plays a more important role in the expression than in the acquisition of a CPP or conditioned motor activity. The mechanism mediating the role of Drd3 in the control of responding by conditioned incentive stimuli remains unknown but it has been found that Drd3 receptors increase in number in the nucleus accumbens during conditioning. Perhaps Drd3 participates in the molecular mechanisms underlying the role of dopamine and of dopamine receptor subtypes in reward-related incentive learning.
引用
收藏
页码:57 / 69
页数:12
相关论文
共 50 条
  • [31] Assessment of dopamine D3 receptor function using D3 receptor knockout mice
    Koeltzow, TE
    Cooper, DC
    Hu, XT
    Xu, M
    Tonegawa, S
    Wolf, ME
    White, FJ
    DOPAMINE RECEPTOR SUBTYPES: FROM BASIC SCIENCE TO CLINICAL APPLICATION, 1998, 19 : 131 - 146
  • [32] D3 dopamine receptor tolerance property: molecular mechanism and physiological relevance
    Gil-Mast, Sara
    Zalcman, Steven
    Kuzhikandathil, Eldo V.
    FASEB JOURNAL, 2010, 24
  • [33] The strength of reward-related learning depends on the degree of activation of ventral tegmental area dopamine neurons
    Galaj, E.
    Ranaldi, R.
    BEHAVIOURAL BRAIN RESEARCH, 2018, 348 : 65 - 73
  • [34] Signaling mechanisms of the D3 dopamine receptor
    Ahlgren-Beekendorf, JA
    Levant, B
    JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, 2004, 24 (03) : 117 - 130
  • [35] The dopamine D3 receptor as a therapeutic target
    Schwartz, JC
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S166 - S167
  • [36] The D3 dopamine receptor and substance dependence
    Richtand, NM
    Goldsmith, RJ
    Nolan, JE
    Berger, SP
    JOURNAL OF ADDICTIVE DISEASES, 2001, 20 (03) : 19 - 32
  • [37] The dopamine D3 receptor and drug addiction
    Pierre Sokoloff
    Bernard Le Foll
    Sylvie Perachon
    Regis Bordet
    Sophie Ridray
    Jean-Charles Schwartz
    Neurotoxicity Research, 2001, 3 : 433 - 441
  • [38] The dopamine D3 receptor and drug addiction
    Sokoloff, Pierre
    Le Foll, Bernard
    Perachon, Sylvie
    Bordet, Regis
    Ridray, Sophie
    Schwartz, Jean-Charles
    NEUROTOXICITY RESEARCH, 2001, 3 (05) : 433 - 441
  • [39] The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors
    Wicke, K
    Garcia-Ladona, J
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 424 (02) : 85 - 90
  • [40] ASSOCIATION BETWEEN DOPAMINE D3 RECEPTOR GENOTYPE AND RESPONSE TO A DOPAMINE D3 RECEPTOR ANTAGONIST IN SCHIZOPHRENIC SUBJECTS.
    Bhathena, A.
    Wang, Y.
    Kraft, J. B.
    Idler, K. B.
    Abel, S. J.
    Holley-Shanks, R. R.
    Robieson, W. Z.
    Spear, B. B.
    Redden, L.
    Katz, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S76 - S76